Financial Performance & Growth - Clover Health achieved Adjusted EBITDA profitability in 2025 and anticipates GAAP Net income in FY26[9, 25] - The company experienced a +33% year-over-year increase in Medicare Advantage (MA) membership[9] - Clover Health's Insurance revenue grew by +39% year-over-year in 3Q YTD[26] - Adjusted SG&A as a percentage of total revenues improved by 370 bps year-over-year in 3Q YTD[23] Clover Assistant & Clinical Outcomes - Clover Assistant is correlated with ~36 months earlier diagnosis & treatment for diabetes on average[18] - Clover Assistant is correlated with ~18 months earlier diagnosis of Chronic Kidney Disease (CKD) stage 3 & higher on average[18] - Clover Assistant is correlated with 18% lower all-cause hospitalizations & 25% lower 30-day readmissions for Congestive Heart Failure (CHF)[18] Market Positioning & Strategy - Clover Health is targeting a ~$500 billion market with >35 million seniors in Medicare Advantage (MA)[9] - The company's PPO-first approach covers 97% of its membership[9] - Clover Health's Medicare Advantage PPO plans received a score of 472 out of 5 Stars on HEDIS Measures for Star Rating Year 2026[51]

Second Quarter 2025 Earnings Conference Call August 5, 2025 LGTMs: Date: Andrew T. (Input) Verbal LGTM 8/1 Peter K. LGTM 8/1 af Legal (Karen / Peter R.) LGTM 8/4 Accounting (#s confirm) LGTM (7/31 - Joe) Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income ...